Both GBM subtypes usually present mutations in the deregulation of different pathways, such as the tumor-suppressor p53 signaling pathway (CDKN2A, MDM2, TP53 genes), NF1 (neurofibromin 1) gene mutations, or TERT (telomerase reverse transcriptase) gene mutations [10,23,24]. This evidence concerns the gene CDKN2A and glioblastoma.